A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer’s Disease in a Clinical Setting-Reference-Cited by-同舟云学术

A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer’s Disease in a Clinical Setting

Published:2017-07-17 Issue:2 Volume:59 Page:603-614
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Iaccarino Leonardo¹²,Chiotis Konstantinos³,Alongi Pierpaolo⁴⁵,Almkvist Ove³⁶⁷,Wall Anders⁸⁹,Cerami Chiara²¹⁰,Bettinardi Valentino⁴,Gianolli Luigi⁴,Nordberg Agneta³⁷,Perani Daniela¹²⁴

Affiliation:

1. Vita-Salute San Raffaele University, Milan, Italy

2. In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

3. Department of NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden

4. Nuclear Medicine Unit, IRCCS San Raffaele Hospital, Milan, Italy

5. Department of Radiological Sciences, Nuclear Medicine Unit, San Raffaele G.Giglio Institute, Cefalù, Italy

6. Department of Psychology, Stockholm University, Stockholm, Sweden

7. Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden

8. Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden

9. PET Centre, Uppsala University Hospital, Uppsala, Sweden

10. Department of Clinical Neurosciences, Neurological Rehabilitation Unit, IRCCS San Raffaele Hospital, Milan, Italy

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference50 articles.

1. Mild cognitive impairment: A concept in evolution;Petersen;J Intern Med,2014

2. Biomarkers for Alzheimer’s disease: Academic, industry and regulatory perspectives;Hampel;Nat Rev Drug Discov,2010

3. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics;Shaw;Nat Rev Drug Discov,2007

4. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Albert;Alzheimers Dement,2011

5. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;McKhann;Alzheimers Dement,2011

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia;BMC Medical Imaging;2024-03-28

2. Modified RCTU Score: A Semi-Quantitative, Visual Tool for Predicting Alzheimer’s Conversion from aMCI;Brain Sciences;2024-01-27

3. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants;The Journal of Prevention of Alzheimer's Disease;2024

4. Montreal Cognitive Assessment in Mild Cognitive Impairment: Relationship with Cerebrospinal Fluid Biomarkers and Conversion to Dementia;Journal of Alzheimer's Disease;2023-11-21

5. Neuroimaging and machine learning for studying the pathways from mild cognitive impairment to alzheimer’s disease: a systematic review;BMC Neurology;2023-08-22